Antibody fragment-polymer conjugates and uses of same
First Claim
1. A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein a disulfide bridge is avoided by substituting another amino acid for the corresponding cysteine residue in the opposite chain of said antibody fragment, and (a), wherein the apparent molecular weight of the conjugate, as determined by size exclusion chromatography is at least about 500 kD, (b) the average actual molecular weight of each nonproteinaceous polymer molecule is at least 20 kD, (c) the conjugate has an apparent size that is at least about 8-fold greater than the apparent size of the parental antibody fragment, (d) the conjugate binds the same antigen as the parental molecule that is not covalently modified by one or two non-proteinaceous polymer molecules, and wherein the antibody fragment comprises an antigen binding site that binds to a polypeptide selected from the group consisting of human vascular endothelial growth factor (VEGF), human CD18, human CD11a, human IgE, human Apo-2 receptor, human tumor necrosis factor-α
- (TNF-α
), human tissue factor (TF), human α
4β
7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α
-chain (TAC).
0 Assignments
0 Petitions
Accused Products
Abstract
Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
-
Citations
127 Claims
-
1. A conjugate consisting essentially of an antibody fragment covalently modified by one or two nonproteinaceous polymer molecules at a free sulfhydryl group of a cysteine residue within the hinge region of the antibody fragment, wherein a disulfide bridge is avoided by substituting another amino acid for the corresponding cysteine residue in the opposite chain of said antibody fragment, and (a), wherein the apparent molecular weight of the conjugate, as determined by size exclusion chromatography is at least about 500 kD, (b) the average actual molecular weight of each nonproteinaceous polymer molecule is at least 20 kD, (c) the conjugate has an apparent size that is at least about 8-fold greater than the apparent size of the parental antibody fragment, (d) the conjugate binds the same antigen as the parental molecule that is not covalently modified by one or two non-proteinaceous polymer molecules, and wherein the antibody fragment comprises an antigen binding site that binds to a polypeptide selected from the group consisting of human vascular endothelial growth factor (VEGF), human CD18, human CD11a, human IgE, human Apo-2 receptor, human tumor necrosis factor-α
- (TNF-α
), human tissue factor (TF), human α
4β
7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α
-chain (TAC). - View Dependent Claims (2, 3, 4, 6, 7, 8, 9, 13, 18, 19, 20, 27, 29, 30, 31, 124, 125, 126, 127)
- (TNF-α
-
5. (canceled)
-
10-12. -12. (canceled)
-
14-17. -17. (canceled)
-
21-26. -26. (canceled)
-
28. (canceled)
-
32-123. -123. (canceled)
Specification